Vivek Yadala
Assistant Professor
Also affiliated: Albert Einstein College of Medicine (2018); Westchester Medical Center (2016); Gandhi Medical College & Hospital (2011); Edwards (United Kingdom) (2020); Apollo Hospitals (2015); Children's Hospital at Montefiore (2018); Edwards Comprehensive Cancer Center (2022); Pediatrics and Genetics (2016); Marshall University (2020–2023)
Faculty Researcher
COM | Internal Med Hem-Onc
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Vivek Yadala's research focuses on the clinical outcomes and treatment of various cancers, particularly lung cancer. He has investigated the prognostic significance of pretreatment neutrophil-lymphocyte ratio in lung cancer patients receiving immunotherapy and analyzed the role of consolidative thoracic and prophylactic cranial radiation in extensive-stage small cell lung cancer within the context of chemo-immunotherapy. His work also includes quality improvement studies related to cancer diagnosis and the value of CT guidance for bone marrow biopsies. Yadala has published on sarcoid-like reactions associated with immunotherapy and has experience with case reports on conditions like cyclic thrombocytopenia and COVID-19 vaccination-associated immune thrombocytopenic purpura. His scholarship metrics include an h-index of 4 with 21 publications and 104 citations.
Metrics
- h-index: 4
- Publications: 21
- Citations: 106
Selected Publications
-
Uterine cancer mortality and demographic disparities in the United States in relation to female obesity. (2026)
-
Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr (2025)
Collaboration Network
Top Collaborators
- Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr
- Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr
- Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr
- Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr
- Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr
- Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr
- Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr
- Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr
- Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr
Similar Researchers
Based on overlapping research topics